– Agreement includes Right of First Refusal for an orthopaedic indication
Heraeus Holding (Heraeus), a Fortune 500 technology group, has announced the completion of an equity investment in Ankasa Regenerative Therapeutics Inc. (Ankasa), a California-based regenerative medicine company.
Ankasa is focused on pharmaceutical preparations for reactivation of stem cells for organ and tissue regrowth, tissue repair and healing. The company is focusing on the development of the stem cell growth factor WNT3A, which is found in humans and functions in the maintenance of bone growth and repair, but the level of which declines with age. Ankasa intends to develop a proprietary localized therapy involving WNT3A for spinal fusion surgery patients as well as the use in additional bone and other tissue repair applications.
Ankasa´s solution is strategically relevant for Heraeus Medical GmbH, a subsidiary of Heraeus Holding. Heraeus Medical, awarded as a TOP 100 innovative company in Germany, develops biomaterials and medical devices for orthopedic surgery, traumatology and biosurgery.
Following recent early-stage investments, Heraeus continues to actively seek enabling technologies and development partners in the burgeoning field of regenerative medicine in order to accelerate its product development pipeline.
Financial terms of the investment by Heraeus were not disclosed.
akampion: When we first met, you were with Paul Capital Partners and very actively scouting the European biotech scene for potential deals. Since then, you have founded TransformRx and now you are also a Director at Alma Bio Therapeutics – how did that come about?
Martin Austin: I left Paul Capital because in my view, the market for royalty funds was beginning to narrow and only companies with sufficient revenues could really fit into the investment model. At the same time, the market trend moved more towards development and R&D. So I was wondering how to address these developments, and so I eventually acquired the Swiss subsidiary of Paul Capital and founded TransformRx GmbH.
Since I know operations in the pharma and the investment industries very well, the idea was to offer financial intermediation services. How can a biotech get money? How to invest in biotech?
akampion: We definitely believe there must have been a market for financial intermediation in the biotech sector – there still is!
Martin Austin: Indeed. But in addition, I also had clients calling up to get support in business development and commercialization, since I have been working in that space for a long time. So I took on these projects and had a request to develop a my commercial BD course with CELforPharma in Brussels into a format for a business development course at the University of Basel. It is part of a Master´s program at the European Center of Pharmaceutical Medicine ECPM which offers a range of training courses in the field of drug development, including leadership and biobusiness development. And then I had an invitation to run a course in China, which I have been running annually since 2007.
akampion: So one project led to another…
Martin Austin: Yes – and it continues! I received similar requests from France and elsewhere which led to my first book on Business Development in the Pharmaceutical Industry being published.The next book is out this year, by the way, and will focus on commercializing IP in healthcare. Just to give you some background, I have also been advising various technology transfer offices for a several years and this sparked the idea for the second book.
akampion: And now you´re also with Alma Bio Therapeutics, a company developing novel antiinflammatory drugs to treat Crohn´s disease and Ulcerative Colitis.
Martin Austin: Right. The CEO is a former “student” of mine. She contacted me because in Israel, the conditions for biotech companies are not very favorable, so the idea was to transfer IP and the company from Israel to Europe. Alma, for example, has a product licensed from the Weizmann Institute. The company is now situated at the Basel incubator and is looking for further funding from angel investors and VCs. The lead product is a synthetic gene sequence encouraging the body to produce a protein called HSP70. HSP70 acts as a transient signal to T-regulatory cells in the immune system which re-harmonises the body’s responses to inflammation. The initial mouse experiments have yielded very good results, so we have a mammalian proof-of-principle – and the manufacturing is already in place as well. I am very glad to be part of the company´s team because I believe that Alma as a start-up company is very well set. So we are ready for investment!
akampion: Thank you, Martin! We will keep our fingers crossed for Alma´s financing and hope to be able to read your new book soon.
These days, everybody has his own opinion about the quality and prospects of the German biotechnology industry. It even seems to be difficult to determine if biotech funding in Germany has increased, remained stable – or dramatically decreased, as recently published by the German industry organization BIO Deutschland.
If you look at key intangibles, such as the extent of media coverage on the biotech sector and the attractiveness of German biotech companies for investment banks, it is obvious that German biotech is not on the rise.
An article by Roland Benedikter and James Giordano published by German newspaper Die Welt suggests a bleak scenario if Germany is not willing to accelerate and intensify its biotech efforts. According to the authors, biotechnology is not only the most important success factor in future economic development – it will also change the global power balance: “the one who controls the chips also controls the game”. Asia and the Far East are quickly catching up in the biotech space, while the U.S. and other European countries continue to heavily invest into the sector. Therefore, Germany might gradually evolve from an export-oriented country to an import-oriented one – unless there will be a fundamental change of mind in the German government and society.
Almost two decades ago, the German biotech industry started out with the clear goal to narrow the gap to the U.S., where biotechnological markets and ventures were (and still are) much more mature. Since then, the German biotech sector has successfully produced a number of promising companies, innovations and products. However, the most attractive and advanced companies and technologies have been acquired by foreign, mostly U.S.-based, companies. Amgen´s take-over of Micromet, an oncology company with academic roots at the University of Munich, is the most recent example.
Therefore, lack of innovation is clearly not the problem. And lack of funding is only the symptom of an underlying German (and partly European) biotech phenomenon – wide-spread risk aversion combined with limited availability of true executive leadership qualities. Moreover, the public sentiment towards biotechnological innovation remains skeptical or even hostile and is mirrored by a “we don’t need this”-attitude of politicians and even Germany’s healthcare system, in which IQWiG, a decision body responsible for drug reimbursement, does its best to belittle innovative medicines.
It may not surprise you that an often-heard German term, “technologiefeindlich” (i.e. a negative attitude towards technological innovation), lacks any English equivalents.